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Abstract—Multi-target and continuous monitoring by wireless
implantable devices is of increasing interest for personalized
therapy. In this work an implantable system is presented which
is capable of measuring different drugs with Cyclic Voltammetry
(CV) method. The wireless microsystem consists of four modules,
namely (i) The inductive coil; (ii) Power management IC;
(iii) Readout and control IC; (iv) Biosensor array. The power
management IC provides 1.8 V with as high as 2 mW power for
the readout IC. The configurable readout IC is able to control the
biosensor array and measure the sensor current in CV method.
CV experiments performed with this microsystem well agree with
a commercial equipment for two well known anti-cancer drugs,
Etoposide and Mitoxantrone, detection.
Index Terms—Cyclic voltammetry measurement; Drug de-
tection; Power management; Inductive coil; Readout circuit;
Integrated circuit.
I. INTRODUCTION
The development of new implantable devices for wireless
and continuous monitoring of the metabolism of drugs in the
human body is required for personalized therapy [1]. Typically
when a group of patients having the same disease receive the
same treatment, the therapeutic output is usually quite different
from patient to patient. This explains the low success rates
obtained in several pharmacological therapies [2].
The design of the implantable monitoring system for long-
term duration has many challenges. First, a multi-target biosen-
sor containing several sensing sites has to be developed in
order to detect several drugs at the same time. The most
common structure of the sensing site has three electrodes:
working electrode (WE), counter electrode (CE) and reference
electrode (RE) [3], where the WE of each sensing site is func-
tionalized to selectively detect a single target drug. Second, in
order to assess biocompatibility by reducing the size and the
weight of the overall implantable system, the biochip should
be batteryless. In addition, the batteries have a limited lifetime
and need to be changed end of their lifetime which increases
the number of surgery operations. In a previous study [4],
a short-range remote powering system is proposed to track
the freely moving animal in a living space and deliver the
sufficient power to the batteryless implanted system.
In this work, we implemented an autonomous microsystem
for Cyclic voltammetry (CV) measurements on anti-cancer
drugs. The implantable microsystem consists of three main
building blocks (i) An inductive coil; (ii) A power manage-
ment IC dealing with the energy source of the implantable
microsystem to provide power; (iii) An interface IC to control
and readout the biosensor; (iv) The biosensor. The power
management unit together with the measurement IC and the
biosensor array are implemented to realize an implantable
and wireless platform to measure multi-target three-electrode
biosensors. Some examples of wireless implantable devices
can be found in literature [5-7], but they are limited to the
monitoring of endogenous molecules detection (i.e. glucose,
lactate) by chronoamperometry.
The quality of the measurement depends on the compati-
bility between the biosensor and the interface electronics as
well as the sufficiency and stability of the supply power during
the measurements. To test the full chain of measurement and
data acquisition, as well as the functionality of each block,
we perform CV measurement on two anti-cancer drugs and
compare the voltamograms with the measurements with a
commercial equipment.
The three main building blocks of the wireless implantable
microsystem are presented in Section II; Section III presents
the measurement method and results on two anti-cancer drugs
based on the CV method by using the integrated circuit.
II. SYSTEM DESIGN
Fig. 1 shows the block diagram of the batteryless im-
plantable bio-chip system for drug monitoring. The detailed
description of the three main building blocks are presented in
the following subsections.
A. Inductive link and power management IC
The implantable system is remotely powered via an opti-
mized inductive link at 13.56 MHz [8]. The power efficiency
of the overall system is dominated by the power transfer
efficiency of the inductive link. Therefore, the link has been
optimized to obtain a good coupling between the coils and
quality factors.
A class-E power amplifier with high drain efficiency is
designed to drive the external coil. To drive the transistor
in the class-E power amplifier, an off-chip oscillator is used.
The induced voltage at the implanted device is proportional
to the frequency. If the frequency increases, the voltage at the
input of the rectifier also increases [8]. On the other hand,
the penetration of the body tissues decrease by the increase
of the frequency [9]. According to the aforementioned trade-
offs, and among the allowed frequency band for inductive
applications introduces in [10], the frequency band of 13.56
MHz is chosen. Moreover this band allows higher magnetic
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Fig. 1. Block diagram view of the implantable biochip with the inductive link
field strength, higher data bandwidth, and less interference
compared to the other standard bands [11].
The induced AC voltage in the internal coil is converted
to DC voltage by an efficient full-wave passive rectifier.
The schematic view of the rectifier is shown in Fig. 2. The
measured power efficiency of the rectifier is 80 % for 2 mW
load.
A low-drop out (LDO) voltage regulator is implemented to
create a clean and stable 1.8 V supply voltage for the bio-
chip system. The high-speed voltage regulator is designed to
suppress the ripples at the remote powering frequency. The
details of the LDO design can be found in [12]. Fig. 3 shows
the Power supply rejection (PSR) value of the regulator. It
shows that the regulator has more than 65dB line regulation
and more than 60dB at 27.12 MHz.
The power level of the implantable biosensor system needs
to be monitored to provide sufficient power for different load
conditions. Also, the coupling between the coils may changes
during the measurement. The transferred power needs to be
adapted dynamically to different load and also coupling condi-
tions. To this purpose, a feedback mechanism is implemented
in which the rectifier voltage (Vrec) is followed and compared
with a certain voltage in order to keep the voltage Vrec at
sufficient level regardless of the load [4]. The output of the
comparator is transmitted to the external base station, as a
power feedback data, to control the supply voltage of the
power amplifier (VPAsup in Fig. 1) [12].
Fig. 4 shows the power feedback system to control the de-
livered power to the implant by adjusting the power amplifier
supply voltage. When the implant power is insufficient, Power
Low data is transmitted to the external base station. As a result,
VPAsup increases by charging the CPAsup and the transmitted
power level is also increased. On the other hand, if Vrec in
the implantable system is higher than necessary, Power High is
transmitted to protect the implant from breakdown. Therefore,
the delivered power is reduced by adapting the supply voltage
of the power amplifier.
Fig. 5 shows the measured output waveform at the output
of rectifier, regulator and the power feedback data when the
inductive link is used for sending power to the IC.
Fig. 2. The schematic view of the Rectifier circuit.
Fig. 3. The (simulated and measured) PSR of the regulator. The regulator
has more than 65dB line regulation and more than 60dB at 27.12 MHz.
B. Control and readout electronics
To control the biosensor in CV measurement, the applied
voltage between the WE and the RE is swept very slowly from
negative voltages to positive voltages, forward and backward.
The resulting current is measured and plotted versus the
applied voltage. To implement the control and readout circuit
for the CV measurement, a triangular waveform generator
and a readout circuit is implemented in 0.18µm which are
described in details in the following subsections.
1) Ramp generator: A Direct Digital Synthesizer (DDS) is
designed to generate a very slow triangular waveform form a 5
kHz clock. The waveform generator is realized by mixed-mode
design methods which consists of a digital up/down counter
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Fig. 4. The schematic view of the power feedback circuit.
Fig. 5. The measured output waveform of the rectifier, regulator and the
power feedback module when the inductive link is used for powering the
system.
and a 9-bit DAC implemented in a resistor ladder scheme.
The conceptual diagram of the ramp generator is shown in
Fig. 6. The generated waveform sweeps the voltage between
200 mV and 1.6 V [13]. The generated waveform goes through
a voltage buffer which acts as a low-pass filter. Using a low
pass filter softens the voltage and reduces the noise.
2) Readout circuit: To control the sensor in CV measure-
ment, a fixed voltage can be applied to the RE through the
potentiostat while the triangular waveform is applied to the
corresponding WE, thereby the differential voltage sweeps
between negative and positive voltages with 1.4 V peak-to-
peak voltage. The bidirectional current readout is realized
through a transimpedance amplifier [13].
The output of the readout circuit is converted to digital data
by a microcontroller. The digitized data is transmitted by an
on-off keying transmitter to the external base-station.
C. Biosensor array design
The microfabricated electrodes made on Silicon substrate
where realized at the centre of Micronano technology of EPFL.
The biosensor size is 30x16.4 mm and consist of an array
of four independent sensors, with WEs of 1.2mm diameter,
REs of 0.41mm2 area and CEs of 2.2mm2 area. The main
advantage behind the design of an array of independent sensors
is the possibility to perform multiplexed measurements of
drugs. More details on the microfabrication and biosensor
design can be found in [14].
III. MEASUREMENTS AND DISCUSSIONS
A. Materials and methods
Milli-Q water (18 MΩ/cm) was used to prepare all aqueous
solutions. All experiments were carried out in a 100 mM
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Fig. 6. The block diagram view of the integrated waveform generator.
Fig. 7. The measurement setup.
Phosphate Buffer Solution ( PBS, pH 7.4) as supporting
electrolyte. Etoposide, and Mitoxantrone, two well known an-
tineoplastic agents, were purchased as a powder from Sigma-
Aldrich. Due to their low solubility in water, both Etoposide,
and Mitoxantrone solutions at different concentration were
prepared by dissolving them in Dimethyl sulfoxide (DMSO,
from Sigma Aldrich) before storing at room temperature. The
biosensor was dip into 10 ml PBS (100 mM, pH 7.4) and drug
samples were added at the right concentration.
B. Measuremnet results
Fig. 7 shows the measurement setup. The measured voltage
waveform at the output of the rectifier, regulator and the
waveform generator are shown in Fig. 8 when the power
management unit (and the inductive link) is used as the supply
voltage of the waveform generator and readout IC.
The electrochemical response of the biosensor was inves-
tigated by cyclic voltammetry at room temperature under
aerobic conditions by applying the triangular waveform with
the slope of 82 mV/sec to the WE and a fixed voltage to the
RE. The measurements were done both with or without the
power management unit. When the power management unit
is not in use, the measurement IC is connected to the supply
voltage of 1.8 V. Fig. 9 shows the acquired voltammograms
for positive applied voltages without the power management
IC. The oxidation current peak is located at voltages 495 mV
and 535 mV for Mitoxantrone and Etoposide, respectively.
CV measurements were also performed using an Auto-
lab PGSTAT128N electrochemical workstation (Metrohm) for
comparison. The same triangular waveform slope and range is
applied to the sensors. The main oxidation peak position and
its location (in voltage) for both measurements are summarized
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Fig. 8. The measured output waveform of the rectifier, regulator and the
waveform generator for cyclic voltammetry when the inductive link is used
for powering the system.
Fig. 9. The measured voltammograms during the detection of Mitoxantrone
(MTX) and Etoposide (ETO) using the readout IC.
in Table I. The measured oxidation current peak location and
value has less than 7% discrepancy between our microsystem
and the Autolab potentiostat. The peak positions are consistent
with the literature [15], [16].
IV. CONCLUSIONS
In this work an implantable microsystem has been designed
and tested to perform drugs measurement in a wireless mode.
The system consists of (i) Inductive link at 13.56 MHz; (ii) An
integrated circuit implementing the rectifier and the regulator
to empower the measurement circuit; (iii) An integrated circuit
to implement triangular waveform generator with sub-Hertz
frequency to control the biosensor in CV measurement, and
readout circuit to measure the sensor current; (iv) A biosensor
array for multi-target detection. The integrated circuits have
been implemented in 0.18µm technology and tested success-
fully. The power efficiency of the full wave passive rectifier is
80% for 2 mW load. The system has been used to measure two
well known anti-cancer drugs (Mitoxantrone and Etoposide)
with CV method. The redox peaks corresponding to the two
compounds were estimated in terms of maximum current
(coding the drugs concentration) and the voltage position
(coding the type of drugs) are measured with less than 7%
discrepancy compare to the commercial equipment. The next
step as the future work would be to complete the integration
of the communication part and perform in-vivo test with mice.
This new development opens the possibility to use implantable
microsystems in personalized chemotherapy.
TABLE I
COMPARISON OF THE MAIN OXIDATION PEAK MEASURED WITH THE
COMMERCIAL EQUIPMENT AND THE IMPLEMENTED MICROSYSTEM.
DISCREPANCY IS LESS THAN 7%.
Autolab Microsystem
Biomolecule
Voltage Current Voltage Current
(mV) (µ A) (mV) (µ A)
Etoposide 495 0.45 495 0.43
Mitoxantrone 535 0.81 513 0.86
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